肝癌患者恶性疾病相关性DNA结合蛋白2的检测

Determination of Malignant Diseaseassociated DNAbinding Protein 2 in Patients with Liver Cancer

为探讨恶性疾病相关性DNA结合蛋白2（MAD2）在肝癌诊断中的价值，采用ELISA法检测了27例原发性肝癌、14例转移性肝癌和12例正常对照组血浆中MAD2的浓度。原发性肝癌、转移性肝癌及正常对照组血浆中MAD2的浓度分别为（30.56±11.38）μg/ml、（9.27±5.58）μg/ml和（8.43±5.62）μg/ml。原发性肝癌患者MAD2浓度明显高于转移性肝癌患者和正常对照组(P<0.001)，转移性肝癌患者和正常对照组MAD2浓度无显著性差异(P>0.05)。结果提示：MAD2在原发性肝癌的诊断中可能是一个有价值的诊断指标。

The aim of this study was to assess the value of malignant disease－associated DNA－binding protein 2(MAD2) in the diagnosis of liver cancer.The concentration of plasma MAD2 was determined in 27 patients with primary liver cancer, 14 patients with metastatic liver cancer and 12 healthy subjects by EL ISA assay. The primary tumors of all the patients with metastatic liver cancer we re located in the gastrointestinal tract, which had been radically resected and had no signs of local recurrence. The concentrations of plasma MAD2 in the pat ients with primary liver cancer, with metastatic liver cancer, and the healthy s ubjects were 30.56*11.38μg/ml, 9.27±5．58μg/ml and 8.43±5.62μg/ml ,res pectively. The concentration of MAD2 in patients with primary liver cancer was signif icantly higher than that in the patients with metastatic liver cancer and health y subjects (P<0.001).There was no significant difference between the health y subjects and the patients with metastatic liver cancer(P>0.05). These res ults suggest that MAD2 may be an useful marker for the diagnosis of primary live r cancer.